About Careers MedBlog Contact us

Diclofenac Gel from Glenmark Pharmaceuticals Receives FDA Approval

by Madhumathi Palaniappan on September 15, 2016 at 12:41 PM
Font : A-A+

Diclofenac Gel from Glenmark Pharmaceuticals Receives FDA Approval

Diclofenac Sodium gel for skin lesion treatment from Glenmark Pharmaceuticals has recently been approved by the United States Food and Drug Administration.

"Glenmark Pharmaceuticals Inc USA has been granted final approval by the USFDA for Diclofenac Sodium gel, 3 per cent, the generic version of Solaraze gel, 3 per cent," the company said in a BSE filing.


"According to IMS Health sales data for the 12-month period ending July 2016, the Solaraze Gel, 3 per cent market achieved annual sales of approximately $297.9 million," it said.

Glenmark's current portfolio consists of 110 products authorised for distribution in the US marketplace and 61 Abbreviated New Drug Applications (ANDAs) are pending for approval with the USFDA.

Source: IANS

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Diclofenac Gel from Glenmark Pharmaceuticals Receives FDA Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests